Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 18/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 16/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 16/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | SLC22A1 | O15245 | 2/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5315866 | 1.00 | SLC6A4 (0.41) | SLC6A4OPRM1SLC6A2OPRD1OPRK1 | |
| SCHEMBL5312303 | 1.00 | SLC6A4 (0.41) | SLC6A4OPRM1SLC6A2OPRD1OPRK1 | |
| SCHEMBL5315862 | 1.00 | SLC6A4 (0.41) | SLC6A4OPRM1SLC6A2OPRD1OPRK1 | |
| SCHEMBL5312306 | 1.00 | SLC6A4 (0.41) | SLC6A4OPRM1SLC6A2OPRD1OPRK1 | |
| SCHEMBL8063149 | 0.82 | TDP1 (0.35) | — | |
| SCHEMBL28217865 | 0.82 | CYP1A2 (0.38) | — | |
| SCHEMBL5655317 | 0.81 | EPHX1 (0.31) | — | |
| SCHEMBL8047946 | 0.81 | EPHX1 (0.34) | — | |
| SCHEMBL28717721 | 0.81 | EPHX1 (0.34) | — | |
| SCHEMBL19667352 | 0.79 | CYP1A2 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1438284-B1 | SYNTHESIS OF ( )-2-((DIMETHYLAMINO)METHYL)-1-(ARYL)CYCLOHEXANOLS | EURO CELTIQUE SA (LU) | 2007-09-26 | — | — | EP | claimed |
| US-6784319-B2 | CONTACTING (+-)-2-((DIMETHYLAMINO)METHYL) CYCLOHEXANONE, A TRANSITION METAL-SALT, AN ORGANIC SOLVENT AND AN ARYL ORGANOMETALLIC COMPOUND TO PROVIDE A CYCLOHEXOXIDE SALT AND PROTONATING | EURO-CELTIQUE, S.A. (LU) | 2004-08-31 | — | — | US | claimed |
| US-20040054209-A1 | Synthesis of (±)-2-((dimethylamino)methyl)-1-(aryl)cyclohexanols | PURDUE PHARMA L.P. | 2004-03-18 | — | — | US | claimed |
| US-20030065221-A1 | Synthesis of (+/-)-2-((dimethylamino)methyl)-1-(aryl)cyclohexanols | PURDUE PHARMA L.P. | 2003-04-03 | — | — | US | claimed |
| EP-1438284-B1 | SYNTHESIS OF ( )-2-((DIMETHYLAMINO)METHYL)-1-(ARYL)CYCLOHEXANOLS | EURO CELTIQUE SA (LU) | 2007-09-26 | — | — | EP | disclosed |
| US-6784319-B2 | CONTACTING (+-)-2-((DIMETHYLAMINO)METHYL) CYCLOHEXANONE, A TRANSITION METAL-SALT, AN ORGANIC SOLVENT AND AN ARYL ORGANOMETALLIC COMPOUND TO PROVIDE A CYCLOHEXOXIDE SALT AND PROTONATING | EURO-CELTIQUE, S.A. (LU) | 2004-08-31 | — | — | US | disclosed |
| EP-1438284-A1 | SYNTHESIS OF ( )-2-((DIMETHYLAMINO)METHYL)-1-(ARYL)CYCLOHEXANOLS | EURO-CELTIQUE S.A. (LU) | 2004-07-21 | — | — | EP | disclosed |
| US-20040054209-A1 | Synthesis of (±)-2-((dimethylamino)methyl)-1-(aryl)cyclohexanols | PURDUE PHARMA L.P. | 2004-03-18 | — | — | US | disclosed |
| US-6649783-B2 | Complexing cyclohexanone compound with transition metal salt | EURO-CELTIQUE, S.A. (LU) | 2003-11-18 | — | — | US | disclosed |
| WO-2003029186-A1 | SYNTHESIS OF (±)-2-((DIMETHYLAMINO)METHYL)-1-(ARYL)CYCLOHEXANOLS | EURO-CELTIQUE, S.A. (LU) | 2003-04-10 | — | — | WO | disclosed |
| US-20030065221-A1 | Synthesis of (+/-)-2-((dimethylamino)methyl)-1-(aryl)cyclohexanols | PURDUE PHARMA L.P. | 2003-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065221-A1 | Synthesis of (+/-)-2-((dimethylamino)methyl)-1-(aryl)cyclohexanols | BHMT2, PNMT, INMT | SLC6A4 831/4885OPRM1 103/4885SLC6A2 616/4885 |
| US-20040054209-A1 | Synthesis of (±)-2-((dimethylamino)methyl)-1-(aryl)cyclohexanols | BHMT2, METTL3, PNMT | SLC6A4 1181/4885OPRM1 127/4885SLC6A2 809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.